Brief: Zymeworks Announces Positive Herizon-GEA-01 Phase 3 Results Supporting Ziihera as Her2-Targeted Agent-Of-Choice And New Standard Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
17/11/2025 11:09
Nov 17 (Reuters) - Zymeworks Inc ZYME.O: ZYMEWORKS ANNOUNCES POSITIVE HERIZON-GEA-01 PHASE 3 RESULTS SUPPORTING ZIIHERA® (ZANIDATAMAB-HRII) AS HER2-TARGETED AGENT-OF-CHOICE AND NEW STANDARD OF CARE IN FIRST-LINE HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA ZYMEWORKS INC: ZYMEWORKS' PARTNER JAZZ INTENDS TO SUBMIT A SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION IN 1H-2026 Source text: nGNX8cMbMB Further company coverage: ZYME.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zymeworks
See all newsUS STOCKS ON THE MOVE-Huron Consulting, RingCentral, Selective Insurance
U.S. STOCKS ON THE MOVE-Huron Consulting, Crown Castle, Bloom Energy
US STOCKS ON THE MOVE-Booz Allen Hamilton, SLB, Deckers Outdoor
US STOCKS ON THE MOVE-American Express, Gorman-Rupp, Moderna
Zymeworks gains on up to $813 million Roche licensing deal for lung cancer drug